Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands.
Academic Center for Thyroid Diseases, Erasmus University Medical Center, Rotterdam, Netherlands.
Nat Rev Dis Primers. 2022 May 19;8(1):30. doi: 10.1038/s41572-022-00357-7.
Hypothyroidism is the common clinical condition of thyroid hormone deficiency and, if left untreated, can lead to serious adverse health effects on multiple organ systems, with the cardiovascular system as the most robustly studied target. Overt primary hypothyroidism is defined as elevated thyroid-stimulating hormone (TSH) concentration in combination with free thyroxine (fT) concentration below the reference range. Subclinical hypothyroidism, commonly considered an early sign of thyroid failure, is defined by elevated TSH concentrations but fT concentrations within the reference range. Hypothyroidism is classified as primary, central or peripheral based on pathology in the thyroid, the pituitary or hypothalamus, or peripheral tissue, respectively. Acquired primary hypothyroidism is the most prevalent form and can be caused by severe iodine deficiency but is more frequently caused by chronic autoimmune thyroiditis in iodine-replete areas. The onset of hypothyroidism is insidious in most cases and symptoms may present relatively late in the disease process. There is a large variation in clinical presentation and the presence of hypothyroid symptoms, especially in pregnancy and in children. Levothyroxine (LT4) is the mainstay of treatment and is one of the most commonly prescribed drugs worldwide. After normalization of TSH and fT concentrations, a considerable proportion of patients treated with LT4 continue to have persistent complaints, compromising quality of life. Further research is needed regarding the appropriateness of currently applied reference ranges and treatment thresholds, particularly in pregnancy, and the potential benefit of LT4/liothyronine combination therapy for thyroid-related symptom relief, patient satisfaction and long-term adverse effects.
甲状腺功能减退症是甲状腺激素缺乏的常见临床病症,如果不进行治疗,可能会导致多个器官系统出现严重的健康不良影响,其中心血管系统是研究最充分的靶器官。显性原发性甲状腺功能减退症定义为促甲状腺激素(TSH)浓度升高,同时游离甲状腺素(fT)浓度低于参考范围。亚临床甲状腺功能减退症通常被认为是甲状腺功能衰竭的早期迹象,其定义为 TSH 浓度升高,但 fT 浓度在参考范围内。甲状腺功能减退症根据甲状腺、垂体或下丘脑或外周组织的病理学分别分类为原发性、中枢性或外周性。获得性原发性甲状腺功能减退症是最常见的形式,可能由严重碘缺乏引起,但在碘充足地区更常由慢性自身免疫性甲状腺炎引起。大多数情况下,甲状腺功能减退症的发病隐匿,症状可能在疾病过程中相对较晚出现。临床表现和甲状腺功能减退症状的存在存在很大差异,尤其是在妊娠和儿童中。左甲状腺素(LT4)是治疗的主要方法,也是世界上最常用的处方药物之一。在 TSH 和 fT 浓度正常化后,相当一部分接受 LT4 治疗的患者仍持续存在持续的不适,影响生活质量。需要进一步研究目前应用的参考范围和治疗阈值的适当性,特别是在妊娠期间,以及 LT4/三碘甲状腺原氨酸联合治疗对甲状腺相关症状缓解、患者满意度和长期不良影响的潜在益处。